Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Filings indexed 849 across all filing types
Latest filing 2015-01-12 Major Shareholding Noti…
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2015
Major Shareholding Notification
2015-01-12 English
Regulatory Filings 2014
Regulatory Filings
2014-12-29 English
SC 13D
Major Shareholding Notification
2014-12-18 English
SC 13D
Major Shareholding Notification
2014-12-12 English
RANDAL J KIRK SC 13D 12-8-2014 (HISTOGENICS CORPORATION)
Major Shareholding Notification
2014-12-10 English
FORM 3
Director's Dealing
2014-12-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.